Fresenius Medical Care AG (NYSE:FMS) Position Trimmed by Cerity Partners LLC

Cerity Partners LLC trimmed its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 9.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,751 shares of the company’s stock after selling 2,925 shares during the period. Cerity Partners LLC’s holdings in Fresenius Medical Care were worth $570,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. QRG Capital Management Inc. increased its position in Fresenius Medical Care by 10.9% in the 2nd quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock valued at $1,151,000 after acquiring an additional 5,946 shares during the period. Signaturefd LLC raised its stake in shares of Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares in the last quarter. Ritholtz Wealth Management lifted its holdings in Fresenius Medical Care by 2.5% in the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock worth $704,000 after purchasing an additional 895 shares during the period. Rhumbline Advisers grew its position in Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after buying an additional 1,128 shares in the last quarter. Finally, Caprock Group LLC acquired a new position in Fresenius Medical Care during the 2nd quarter valued at about $208,000. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $24.06 on Friday. The company has a market capitalization of $14.12 billion, a PE ratio of 19.88, a price-to-earnings-growth ratio of 0.95 and a beta of 0.94. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock has a fifty day moving average of $21.23 and a 200-day moving average of $20.37. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $24.31.

Wall Street Analyst Weigh In

FMS has been the subject of a number of research analyst reports. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. StockNews.com initiated coverage on Fresenius Medical Care in a report on Thursday, November 28th. They issued a “strong-buy” rating for the company. Truist Financial lifted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Berenberg Bank began coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.